SGLT-2 inhibitors cut risk of death in diabetics, data shows

13th March 2018 Uncategorised 0

AstraZeneca has unveiled findings of a new analysis of data from the CVD-REAL study, showing a significant cut in the risk of all-cause death (ACD) in patients with type II diabetes taking SGLT-2 inhibitors.

More: SGLT-2 inhibitors cut risk of death in diabetics, data shows
Source: News